Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 1/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.43 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.43 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16920345 | 1.00 | CTSC (0.44) | CTSCGRIK1AGTR2GRIA2ALDH1A1 | |
| SCHEMBL1768681 | 1.00 | CTSC (0.44) | CTSCGRIK1AGTR2GRIA2ALDH1A1 | |
| SCHEMBL1006317 | 1.00 | CTSC (0.44) | CTSCGRIK1AGTR2GRIA2ALDH1A1 | |
| SCHEMBL6374726 | 1.00 | CTSC (0.44) | CTSCGRIK1AGTR2GRIA2ALDH1A1 | |
| SCHEMBL1006306 | 1.00 | CTSC (0.44) | CTSCGRIK1AGTR2GRIA2ALDH1A1 | |
| SCHEMBL5802417 | 1.00 | CTSC (0.44) | CTSCGRIK1AGTR2GRIA2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL7449326 | 0.98 | GRIK1 (0.45) | CTSCGRIK1AGTR2GRIA2CTSL | |
| Hydrochloric Acid SCHEMBL5862746 | 0.98 | GRIK1 (0.45) | CTSCGRIK1AGTR2GRIA2CTSL | |
| Hydrochloric Acid SCHEMBL5862743 | 0.98 | GRIK1 (0.45) | CTSCGRIK1AGTR2GRIA2CTSL | |
| SCHEMBL8881468 | 0.93 | CTSC (0.40) | CTSCGRIK1AGTR2GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4196608-B1 | NUCLEOSIDE-5'-OLIGOPHOSPHATES TAGGED WITH POSITIVELY-CHARGED POLYMERS, NANOPORES INCORPORATING NEGATIVE CHARGES, AND METHODS AND SYSTEMS USING THE SAME | HOFFMANN LA ROCHE (CH) | 2024-10-23 | — | — | EP | claimed |
| US-20240150824-A1 | NUCLEOSIDE-5'-OLIGOPHOSPHATES TAGGED WITH POSTIVIELY-CHARGED POLYMERS, NANOPORES INCORPORATING NEGATIVE CHARGES, AND METHODS AND SYSTEMS USING THE SAME | ROCHE SEQUENCING SOLUTIONS INC (US) | 2024-05-09 | — | — | US | claimed |
| EP-4196608-A1 | NUCLEOSIDE-5'-OLIGOPHOSPHATES TAGGED WITH POSITIVELY-CHARGED POLYMERS, NANOPORES INCORPORATING NEGATIVE CHARGES, AND METHODS AND SYSTEMS USING THE SAME | F. Hoffmann-La Roche AG (CH) | 2023-06-21 | — | — | EP | claimed |
| WO-2022033998-A1 | NUCLEOSIDE-5'-OLIGOPHOSPHATES TAGGED WITH POSITIVELY-CHARGED POLYMERS, NANOPORES INCORPORATING NEGATIVE CHARGES, AND METHODS AND SYSTEMS USING THE SAME | F. HOFFMANN-LA ROCHE AG (CH) | 2022-02-17 | — | — | WO | claimed |
| CN-1310629-A | Combined administration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions | WARNER LAMBERT CO (US) | 2001-08-29 | — | — | CN | claimed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | claimed |
| EP-0552417-B1 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1999-07-07 | — | — | EP | claimed |
| US-5707985-A | Naphthyl-, quinolyl- and isoquinolyl- sulfonamide derivatives as cell adhesion modulators | TANABE SEIYAKU CO. LTD. (JP) | 1998-01-13 | — | — | US | claimed |
| EP-0528312-B1 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1997-07-16 | — | — | EP | claimed |
| EP-0714909-A1 | Composition for prophylaxis or treatment of pulmonary circulatory diseases | Takeda Chemical Industries, Ltd. (JP) | 1996-06-05 | — | — | EP | claimed |
| EP-4196608-B1 | NUCLEOSIDE-5'-OLIGOPHOSPHATES TAGGED WITH POSITIVELY-CHARGED POLYMERS, NANOPORES INCORPORATING NEGATIVE CHARGES, AND METHODS AND SYSTEMS USING THE SAME | HOFFMANN LA ROCHE (CH) | 2024-10-23 | — | — | EP | disclosed |
| US-20240150824-A1 | NUCLEOSIDE-5'-OLIGOPHOSPHATES TAGGED WITH POSTIVIELY-CHARGED POLYMERS, NANOPORES INCORPORATING NEGATIVE CHARGES, AND METHODS AND SYSTEMS USING THE SAME | ROCHE SEQUENCING SOLUTIONS INC (US) | 2024-05-09 | — | — | US | disclosed |
| EP-4196608-A1 | NUCLEOSIDE-5'-OLIGOPHOSPHATES TAGGED WITH POSITIVELY-CHARGED POLYMERS, NANOPORES INCORPORATING NEGATIVE CHARGES, AND METHODS AND SYSTEMS USING THE SAME | F. Hoffmann-La Roche AG (CH) | 2023-06-21 | — | — | EP | disclosed |
| US-20230040236-A1 | Diamine-Linked Melanocortin Receptor-Specific Cyclic Peptides for Ocular Indications | PALATIN TECHNOLOGIES, INC. (US) | 2023-02-09 | — | — | US | disclosed |
| EP-0626174-A2 | Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-11-30 | — | — | EP | disclosed |
| EP-0552417-A1 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-07-28 | — | — | EP | disclosed |
| EP-0528312-A2 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-02-24 | — | — | EP | disclosed |
| EP-0490667-A2 | HIV protease inhibitors | JAPAN ENERGY CORPORATION (JP) | 1992-06-17 | — | — | EP | disclosed |
| US-4206122-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1980-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230040236-A1 | Diamine-Linked Melanocortin Receptor-Specific Cyclic Peptides for Ocular Indications | MC1R, MC3R, MC5R | CTSC 291/4885GRIK1 935/4885AGTR2 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.